GENMAB Inactive Instrument
Genmab Share Price Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,025 DKK | +66.39% |
|
+4.14% | +14.24% |
| 05-03 | GENMAB : A good start to 2024; guidance unchanged |  |
| 05-03 | Genmab Posts Q1 Net Profit Surge; Revenue Jumps | MT |
| Sales 2024 * | 19.8B 2.87B 228B | Sales 2025 * | 23.62B 3.43B 272B | Capitalization | 129B 18.65B 1,482B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 679M 53.98B | Net income 2025 * | 6.63B 962M 76.42B | EV / Sales 2024 * | 5.16 x |
| Net cash position 2024 * | 26.36B 3.82B 304B | Net cash position 2025 * | 33.63B 4.88B 388B | EV / Sales 2025 * | 4.02 x |
| P/E ratio 2024 * |
29.2
x | P/E ratio 2025 * |
21
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
01/08/2024
- Q2 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +4.52% | 111B | |
| +11.12% | 105B | |
| -11.94% | 22.34B | |
| -3.78% | 21.93B | |
| -35.21% | 18.12B | |
| -9.23% | 16.96B | |
| +3.15% | 13.7B | |
| +36.99% | 12.45B | |
| +291.11% | 7.98B |
